Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Breast 1

Conditions

Carcinoma 2Breast Neoplasms 2Vomiting 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumors 1Sarcoma 1Postoperative Nausea and Vomiting 1Neoplasm Metastasis 1Multiple Myeloma 1Liposarcoma 1Leukemia, Hairy Cell 1Histiocytoma, Malignant Fibrous 1Dermatofibrosarcoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Carcinoma In Situ 1Adenocarcinoma, Mucinous 1

Interventions

pembrolizumab 25Cisplatin 23Carboplatin 18Magnetic Resonance Spectroscopy 16Paclitaxel 15Specimen Handling 14Pemetrexed 11durvalumab 9Radiotherapy, Intensity-Modulated 8Platinum 81,2-diaminocyclohexaneplatinum II citrate 8Nivolumab 7Radiation 6Docetaxel 6Cetuximab 6Biopsy 6osimertinib 5cemiplimab 5Taxes 5Radiotherapy 5Ipilimumab 5Cyclophosphamide 51-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 5poly ICLC 4cabozantinib 4atezolizumab 4Oxaliplatin 4Gemcitabine 4Fluorouracil 4Bevacizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma × Famotidine × 1 year × Clear all
NCT05977998 2026-05-22

A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology

M.D. Anderson Cancer Center

Phase 2 Recruiting
30 enrolled
Tumor-Agnostic

Carcinoma

NCT05035407 2025-12-02

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
36 enrolled 7 charts
Breast

Carcinoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡